Triple Threat: New Hair Loss Drug Combining Three Active Ingredients Enters Final Trial Stage

MONTRÉAL, QC – April 02, 2026 – Canadian biotechnology firm Triple Hair Group Inc. has officially begun the final and most critical stage of testing for its new male pattern baldness treatment, TH07. The company announced it has dosed the first patient in its Phase III clinical trial, a pivotal step that moves the promising topical therapy closer to potentially becoming a new prescription standard for the hundreds of millions of men affected by androgenic alopecia worldwide.

The trial will evaluate TH07, a patented topical spray that uniquely combines three separate, well-documented ingredients into a single, multi-pronged treatment. This milestone launches a crucial data-gathering phase that will determine the drug's future and could reshape a global hair loss market projected to exceed $16 billion by 2030.

A Multi-Pronged Attack on Androgenic Alopecia

What sets TH07 apart from the current mainstays of hair loss treatment is its innovative, multi-mechanism approach. The prescription formula integrates three active ingredients—minoxidil, finasteride, and latanoprost—into one topical solution, each targeting a different biological pathway implicated in hair loss.

• Minoxidil, a well-known vasodilator and the active ingredient in over-the-counter products like Rogaine, works by widening blood vessels around the hair follicles. This increases blood flow, delivering more oxygen and nutrients to stimulate and prolong the hair's anagen, or growth, phase.

• Finasteride, commonly prescribed orally as Propecia, is a 5-alpha-reductase inhibitor. It directly tackles the hormonal cause of male pattern baldness by blocking the conversion of testosterone into dihydrotestosterone (DHT), the androgen responsible for shrinking hair follicles.

• Latanoprost, a prostaglandin analog primarily used to treat glaucoma, was observed to increase eyelash growth as a side effect. In TH07, it is intended to mimic the body's natural prostaglandins to awaken dormant hair follicles and push them from a resting phase into an active growth phase.

By combining these complementary actions, TH07 is designed to simultaneously stimulate follicle activity, reduce the hormonal damage that causes miniaturization, and extend the natural growth cycle of the hair. This synergistic strategy is at the heart of the company's confidence. Earlier proof-of-concept studies yielded encouraging results, with 82% of participants showing positive outcomes. In that study, 52% of men using TH07 demonstrated dense hair regrowth, a stark contrast to the 50-77% of men in monotherapy groups (using only one of the ingredients) who showed no growth at all.

"This study is expected to provide important data on whether a multi-mechanism topical therapy such as TH07 can improve treatment outcomes for patients,” noted Dr. Martin Braun, the Principal Medical Investigator for the Phase III trial.

Navigating a Crowded, Multi-Billion Dollar Market

The initiation of this trial places Triple Hair at the forefront of a highly competitive and lucrative market. The global hair loss treatment industry was valued at approximately $8.8 billion in 2023, with androgenetic alopecia treatments making up a significant portion. For decades, the market has been dominated by topical minoxidil and oral finasteride, but both have limitations.

While effective for many, oral finasteride carries a risk of systemic side effects, including sexual dysfunction and mood changes, which deters some users. Minoxidil's effectiveness can be limited and may cause scalp irritation. The need for a more effective, convenient, and safer alternative has created a significant unmet need.

Triple Hair's strategy with TH07 directly addresses these gaps. By formulating finasteride for topical use, the company aims to deliver the DHT-blocking benefits directly to the scalp, potentially minimizing systemic absorption and its associated risks. Combining it with minoxidil and latanoprost in a single, once-daily spray also addresses patient compliance, simplifying the treatment regimen.

"Androgenic alopecia affects hundreds of millions of men globally and remains an area of significant unmet need, with limited effective treatment options available," said Jean-Philippe Gravel, President and CEO of Triple Hair. "We believe TH07’s differentiated multi-mechanism approach has the potential to offer a meaningful new prescription treatment option in a large and underserved market."

The Path to Approval: What Lies Ahead for TH07

The journey to market approval now hinges on the success of the Phase III trial, registered as NCT07435012. The 24-week, randomized, double-blind, placebo-controlled study is considered the gold standard in clinical research. It is designed to enroll 420 male participants with moderate to moderately advanced androgenic alopecia across up to 10 clinical sites in Canada.

During the trial, participants will be randomly assigned to receive either TH07 or a placebo, with neither the patients nor the investigators knowing who is receiving the active treatment. This design eliminates bias and will provide robust data on both the efficacy and safety of the drug.

Triple Hair, founded in 2013, has been methodically building towards this moment. The company recently secured a $4 million financing round to accelerate its clinical trials, backed by investors including Prevail Partners and government bodies like the New Brunswick Innovation Fund and Investissement Québec. This funding supports not only the Canadian trial but also the company's global ambitions, which include regulatory approvals received in Europe and plans for a similar trial in India.

The results of this pivotal study will be eagerly anticipated by dermatologists, investors, and millions of men seeking a better solution for hair loss. A successful outcome would not only validate Triple Hair's scientific approach but could also establish a new therapeutic benchmark, transforming the standard of care for androgenic alopecia.